Back to Search Start Over

Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children

Authors :
Lee, Pui Y.
Day-Lewis, Megan
Henderson, Lauren A.
Friedman, Kevin G.
Lo, Jeffrey
Roberts, Jordan E.
Lo, Mindy S.
Platt, Craig D.
Chou, Janet
Hoyt, Kacie J.
Baker, Annette L.
Banzon, Tina M.
Chang, Margaret H.
Cohen, Ezra
de Ferranti, Sarah D.
Dionne, Audrey
Habiballah, Saddiq
Halyabar, Olha
Hausmann, Jonathan S.
Hazen, Melissa M.
Janssen, Erin
Meidan, Esra
Nelson, Ryan W.
Nguyen, Alan A.
Sundel, Robert P.
Dedeoglu, Fatma
Nigrovic, Peter A.
Newburger, Jane W.
Son, Mary Beth F.
Source :
Journal of Clinical Investigation. November, 2020, Vol. 130 Issue 11, p5942, 9 p.
Publication Year :
2020

Abstract

BACKGROUND. Pediatric SARS-CoV-2 infection can be complicated by a dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C). The clinical and immunologic spectrum of MIS-C and its relationship to other inflammatory conditions of childhood have not been studied in detail. METHODS. We retrospectively studied confirmed cases of MIS-C at our institution from March to June 2020. The clinical characteristics, laboratory studies, and treatment response were collected. Data were compared with historic cohorts of Kawasaki disease (KD) and macrophage activation syndrome (MAS). RESULTS. Twenty-eight patients fulfilled the case definition of MIS-C. Median age at presentation was 9 years (range: 1 month to 17 years); 50% of patients had preexisting conditions. All patients had laboratory confirmation of SARS- CoV-2 infection. Seventeen patients (61%) required intensive care, including 7 patients (25%) who required inotrope support. Seven patients (25%) met criteria for complete or incomplete KD, and coronary abnormalities were found in 6 cases. Lymphopenia, thrombocytopenia, and elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common but not ubiquitous. Cytopenias distinguished MIS-C from KD and the degree of hyperferritinemia and pattern of cytokine production differed between MIS-C and MAS. Immunomodulatory therapy given to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%). Clinical and laboratory improvement were observed in all cases, including 6 cases that did not require immunomodulatory therapy. No mortality was recorded in this cohort. CONCLUSION. MIS-C encompasses a broad phenotypic spectrum with clinical and laboratory features distinct from KD and MAS. FUNDING. This work was supported by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Allergy and Infectious Diseases; Rheumatology Research Foundation Investigator Awards and Medical Education Award; Boston Children's Hospital Faculty Career Development Awards; the McCance Family Foundation; and the Samara Jan Turkel Center.<br />Introduction Since the onset of the Coronavirus disease 2019 (COVID-19) pandemic, millions of individuals have been infected with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and more than 500,000 deaths [...]

Details

Language :
English
ISSN :
00219738
Volume :
130
Issue :
11
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.641057634
Full Text :
https://doi.org/10.1172/JCI141113